Santhera Pharmaceuticals Holding AG (XSWX:SANN) Valuation Rank


XSWX:SANN Santhera Pharmaceuticals Holding AG XSWX:SANN
39 GF Score
Price CHF15.96
GF Value CHF23.15
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Santhera Pharmaceuticals Holding AG Valuation Rank Related Terms

XSWX:SANN
39GF Score
Santhera Pharmaceuticals Holding AG XSWX:SANN
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of CHF15.96 is trading 31.1% below its estimated GF Value™ of CHF23.15. GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.

Key valuation signals for XSWX:SANN:

  • Valuation Rank:
  • GF Value™: CHF23.15 vs. price of CHF15.96 (31.1% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score

Get the complete analysis for XSWX:SANN

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF15.96
Price
CHF23.15
GF Value